Abstract
Patients with advanced or metastatic colorectal cancer ((m)CRC) have limited effective treatment options resulting in high mortality rates. A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment. However, of around 42 TKIs demonstrating preclinical anti-tumour activity, and despite numerous clinical trials, only 1 has been approved for clinical use in mCRC. Clearly, there is a huge gap in the translation of these targeted therapies to the clinic. This underlines the limitations of preclinical models to predict clinical drug efficacy and to fully characterize the mechanism of action. Moreover, several relevant topics remain poorly resolved. Do we know the actual intracellular concentrations that are required for anticancer efficacy, and what range of intra-tumoral drug concentrations is reached in clinical setting? Are the intended targeted kinases responsible for the anti-cancer activity or are other unexpected cellular targets involved? Do we have any idea of the effect of these drugs on the tumour microenvironment and does this help explain therapy success, failure or heterogeneity? In this review, we address these questions and discuss concepts that jointly complicate the clinical translation of TKIs for CRC. Finally, we will argue that an integrated approach with more sophisticated preclinical models and techniques may improve the prediction of clinical treatment efficacy.
Original language | English |
---|---|
Article number | 102466 |
Journal | Cancer treatment reviews |
Volume | 110 |
DOIs | |
Publication status | Published - 1 Nov 2022 |
Externally published | Yes |
Keywords
- Colorectal cancer
- Preclinical models
- Translational gaps
- Tyrosine kinase inhibitors
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
Iyer, K. K., van Erp, N. P., Tauriello, D. V. F., Verheul, H. M. W., & Poel, D. (2022). Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer treatment reviews, 110, Article 102466. https://doi.org/10.1016/j.ctrv.2022.102466
Iyer, Kirti K. ; van Erp, Nielka P. ; Tauriello, Daniele V. F. et al. / Lost in translation : Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. In: Cancer treatment reviews. 2022 ; Vol. 110.
@article{7e775188f4e24e11a78c1f066a72c72c,
title = "Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer",
abstract = "Patients with advanced or metastatic colorectal cancer ((m)CRC) have limited effective treatment options resulting in high mortality rates. A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment. However, of around 42 TKIs demonstrating preclinical anti-tumour activity, and despite numerous clinical trials, only 1 has been approved for clinical use in mCRC. Clearly, there is a huge gap in the translation of these targeted therapies to the clinic. This underlines the limitations of preclinical models to predict clinical drug efficacy and to fully characterize the mechanism of action. Moreover, several relevant topics remain poorly resolved. Do we know the actual intracellular concentrations that are required for anticancer efficacy, and what range of intra-tumoral drug concentrations is reached in clinical setting? Are the intended targeted kinases responsible for the anti-cancer activity or are other unexpected cellular targets involved? Do we have any idea of the effect of these drugs on the tumour microenvironment and does this help explain therapy success, failure or heterogeneity? In this review, we address these questions and discuss concepts that jointly complicate the clinical translation of TKIs for CRC. Finally, we will argue that an integrated approach with more sophisticated preclinical models and techniques may improve the prediction of clinical treatment efficacy.",
keywords = "Colorectal cancer, Preclinical models, Translational gaps, Tyrosine kinase inhibitors",
author = "Iyer, {Kirti K.} and {van Erp}, {Nielka P.} and Tauriello, {Daniele V. F.} and Verheul, {Henk M. W.} and Dennis Poel",
note = "Funding Information: DVFT is funded by a Hypatia Fellowship from the Radboudumc. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
month = nov,
day = "1",
doi = "10.1016/j.ctrv.2022.102466",
language = "English",
volume = "110",
journal = "Cancer treatment reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
}
Iyer, KK, van Erp, NP, Tauriello, DVF, Verheul, HMW & Poel, D 2022, 'Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer', Cancer treatment reviews, vol. 110, 102466. https://doi.org/10.1016/j.ctrv.2022.102466
Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. / Iyer, Kirti K.; van Erp, Nielka P.; Tauriello, Daniele V. F. et al.
In: Cancer treatment reviews, Vol. 110, 102466, 01.11.2022.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Lost in translation
T2 - Revisiting the use of tyrosine kinase inhibitors in colorectal cancer
AU - Iyer, Kirti K.
AU - van Erp, Nielka P.
AU - Tauriello, Daniele V. F.
AU - Verheul, Henk M. W.
AU - Poel, Dennis
N1 - Funding Information:DVFT is funded by a Hypatia Fellowship from the Radboudumc.Publisher Copyright:© 2022 The Author(s)
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Patients with advanced or metastatic colorectal cancer ((m)CRC) have limited effective treatment options resulting in high mortality rates. A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment. However, of around 42 TKIs demonstrating preclinical anti-tumour activity, and despite numerous clinical trials, only 1 has been approved for clinical use in mCRC. Clearly, there is a huge gap in the translation of these targeted therapies to the clinic. This underlines the limitations of preclinical models to predict clinical drug efficacy and to fully characterize the mechanism of action. Moreover, several relevant topics remain poorly resolved. Do we know the actual intracellular concentrations that are required for anticancer efficacy, and what range of intra-tumoral drug concentrations is reached in clinical setting? Are the intended targeted kinases responsible for the anti-cancer activity or are other unexpected cellular targets involved? Do we have any idea of the effect of these drugs on the tumour microenvironment and does this help explain therapy success, failure or heterogeneity? In this review, we address these questions and discuss concepts that jointly complicate the clinical translation of TKIs for CRC. Finally, we will argue that an integrated approach with more sophisticated preclinical models and techniques may improve the prediction of clinical treatment efficacy.
AB - Patients with advanced or metastatic colorectal cancer ((m)CRC) have limited effective treatment options resulting in high mortality rates. A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment. However, of around 42 TKIs demonstrating preclinical anti-tumour activity, and despite numerous clinical trials, only 1 has been approved for clinical use in mCRC. Clearly, there is a huge gap in the translation of these targeted therapies to the clinic. This underlines the limitations of preclinical models to predict clinical drug efficacy and to fully characterize the mechanism of action. Moreover, several relevant topics remain poorly resolved. Do we know the actual intracellular concentrations that are required for anticancer efficacy, and what range of intra-tumoral drug concentrations is reached in clinical setting? Are the intended targeted kinases responsible for the anti-cancer activity or are other unexpected cellular targets involved? Do we have any idea of the effect of these drugs on the tumour microenvironment and does this help explain therapy success, failure or heterogeneity? In this review, we address these questions and discuss concepts that jointly complicate the clinical translation of TKIs for CRC. Finally, we will argue that an integrated approach with more sophisticated preclinical models and techniques may improve the prediction of clinical treatment efficacy.
KW - Colorectal cancer
KW - Preclinical models
KW - Translational gaps
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85139077272&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2022.102466
DO - 10.1016/j.ctrv.2022.102466
M3 - Review article
C2 - 36183569
SN - 0305-7372
VL - 110
JO - Cancer treatment reviews
JF - Cancer treatment reviews
M1 - 102466
ER -
Iyer KK, van Erp NP, Tauriello DVF, Verheul HMW, Poel D. Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer treatment reviews. 2022 Nov 1;110:102466. doi: 10.1016/j.ctrv.2022.102466